Stem-cell technology company Bio-Restorative Therapies Inc. named Gregory Lutz chief medical advisor for spine medicine, effective Feb. 20. In a newly created post, Lutz will help the firm prepare its investigational new drug/investigational device exemption for its brtxDISC non-surgical treatment for bulging and herniated lumbar discs. Lutz is associate professor for clinical rehabilitation medicine at Weill Medical College of Cornell University in New York, and an attending physician at the Hospital for Special Surgery.
People Briefs: Bio-Restorative Therapies; Spine Medicine; Caliber
Bio-Restorative Therapies names chief medical advisor of spine medicine. Caliber Imaging & Diagnostics appoints VP of U.S. Sales. Harvard Bioscience adds VP, global operations and quality. More people news.
More from Leadership
More from Medtech Insight
• By
The FDA staff cuts will probably mean longer device review times at least in the short term, speakers said at a recent webinar. But innovations like AI and third-party review could offer some hope, even as tariffs create a new set of problems.
• By
Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.
• By
Now that a federal judge has ruled the US FDA exceeded its authority by unilaterally assuming regulatory oversight of lab-developed tests, what’s the agency’s next move? And does it really have one?